NIH RADx® Initiative
NIH began the Rapid Acceleration of Diagnostics (RADx®) initiative to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The program funds research examining how existing technologies can be easier to use, easier to access and more accurate. RADx® also seeks opportunities to advance diagnostic technologies through the development pipeline so they can be broadly available to Americans, including those most vulnerable to and/or disproportionately impacted by COVID-19. Read more about the RADx® initiative.
COVID-19 Serology Dashboard (SeroHub)
NIAID, in collaboration with the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC), developed the COVID-19 Seroprevalence Studies Hub (SeroHub), a data repository where seroprevalence studies are systematically presented through an interactive interface. Users can explore and download data from hundreds of seroprevalence studies conducted in the United States to visualize trends over time, geography, population, age, and antigen target to understand the proportion of the population either vaccinated against SARS-CoV-2, previously infected with the virus, or both. Visit the COVID-19 SeroHub.